Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas by Wallace, P.W. et al.
Metabolomics, machine learning and immunohistochemistry to
predict succinate dehydrogenase mutational status in
phaeochromocytomas and paragangliomas
Paal W Wallace1 , Catleen Conrad1, Sascha Brückmann2, Ying Pang3, Eduardo Caleiras4, Masanori Murakami5,
Esther Korpershoek6, Zhengping Zhuang7, Elena Rapizzi8, Matthias Kroiss9, Volker Gudziol10,11, Henri JLM Timmers12,
Massimo Mannelli8, Jens Pietzsch14,15, Felix Beuschlein5,16, Karel Pacak3, Mercedes Robledo17, Barbara Klink18,19,
Mirko Peitzsch1, Anthony J Gill20,21,22, Arthur S Tischler23, Ronald R de Krijger24,25, Thomas Papathomas26,
Daniela Aust27, Graeme Eisenhofer1,13 and Susan Richter1*
1 Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany
2 Institute of Pathology, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
3 Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
4 Histopathology Core Unit, Spanish National Cancer Research Centre (CNIO), Calle de Melchor Fernández Almagro, Madrid, Spain
5 Medizinische Klinik and Poliklinik IV, Ludwig-Maximilians-Universität München, Munich, Germany
6 Department of Pathology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands
7 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
8 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
9 Department of Internal Medicine, Division of Endocrinology, University Hospital, University of Würzburg, Würzburg, Germany
10 Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie, Plastische Operationen, Städtisches Klinikum Dresden, Akademisches
Lehrkrankenhaus der Technischen Universität Dresden, Dresden, Germany
11 Departments of Otorhinolaryngology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
12 Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands
13 Department of Medicine III, University Hospital Dresden, Dresden, Germany
14 Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-
Rossendorf, Dresden, Germany
15 Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, Germany
16 Department for Endocrinology, Diabetology and Clinical Nutrition, UniversitätsSpital Zürich, Zurich, Switzerland
17 Hereditary Endocrine Cancer Group, CNIO, Madrid, Spain and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER),
Madrid, Spain
18 Institute for Clinical Genetics, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
19 Department of Genetics, Laboratoire National de Santé, Dudelange, Luxembourg
20 Royal North Shore Hospital, Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Sydney, Australia
21 School of Medicine, University of Sydney, Sydney, Australia
22 NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia
23 Department of Pathology and Laboratory Medicine, Tufts University School of Medicine, Boston, MA, USA
24 Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
25 Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
26 Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, UK
27 Institute of Pathology, Tumor and Normal Tissue Bank of the UCC/NCT Dresden, University Hospital Carl Gustav Carus, Technische Universität
Dresden, Dresden, Germany
*Correspondence to: S Richter, Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Fetscherstraße 74,
01307 Dresden, Germany. E-mail: susan.richter@uniklinikum-dresden.de
Abstract
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with a hereditary background in
over one-third of patients. Mutations in succinate dehydrogenase (SDH) genes increase the risk for PPGLs and several
other tumours. Mutations in subunit B (SDHB) in particular are a risk factor for metastatic disease, further highlight-
ing the importance of identifying SDHx mutations for patient management. Genetic variants of unknown signifi-
cance, where implications for the patient and family members are unclear, are a problem for interpretation. For
such cases, reliable methods for evaluating protein functionality are required. Immunohistochemistry for SDHB
(SDHB-IHC) is the method of choice but does not assess functionality at the enzymatic level. Liquid chromatogra-
phy–mass spectrometry-based measurements of metabolite precursors and products of enzymatic reactions provide
an alternative method. Here, we compare SDHB-IHC with metabolite profiling in 189 tumours from 187 PPGL
patients. Besides evaluating succinate:fumarate ratios (SFRs), machine learning algorithms were developed to estab-
lish predictive models for interpreting metabolite data. Metabolite profiling showed higher diagnostic specificity
compared to SDHB-IHC (99.2% versus 92.5%, p = 0.021), whereas sensitivity was comparable. Application of
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machine learning algorithms to metabolite profiles improved predictive ability over that of the SFR, in particular for
hard-to-interpret cases of head and neck paragangliomas (AUC 0.9821 versus 0.9613, p = 0.044). Importantly, the
combination of metabolite profiling with SDHB-IHC has complementary utility, as SDHB-IHC correctly classified all
but one of the false negatives from metabolite profiling strategies, while metabolite profiling correctly classified all
but one of the false negatives/positives from SDHB-IHC. From 186 tumours with confirmed status of SDHx variant
pathogenicity, the combination of the two methods resulted in 185 correct predictions, highlighting the benefits of
both strategies for patient management.
© 2020 The Authors. The Journal of Pathology published by JohnWiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Mitochondrial enzymes, such as succinate dehydroge-
nase (SDH), or complex II of the respiratory chain, play
a central role in energy homeostasis within the cell. The
complex is made up of four subunits (SDHA, SDHB,
SDHC, and SDHD) and assembly is assisted by several
factors, including SDHAF2. Mutations of genes encod-
ing these proteins can result in phaeochromocytomas
and paragangliomas (PPGLs), gastrointestinal stromal
tumours, renal cell carcinomas, and pituitary adenomas
[1]. The mutations occur almost exclusively in the germ-
line, leaving the patient and potentially family members
at lifelong risk for disease. Mutations in SDHB in partic-
ular predispose to metastatic PPGL and are associated
with increased mortality [2,3]. Endocrine guidelines
therefore advise that genetic testing should be offered
to all patients with PPGL [4].
With advances in gene sequencing techniques and
decreasing costs, genetic testing is becoming more prac-
tical and widely available, but this has also led to new
challenges [5]. Variants of unknown significance, where
the functional impact of the mutation has not been estab-
lished, are increasingly troublesome. Also, even with
advanced genetic testing, some functional variants or
mutations may be missed. This includes intronic variants
and epimutations, as well as mutations in other genes
impacting mitochondrial energymetabolism [6–8]. Such
problems can be addressed by methods assessing the
functionality of involved proteins, thereby allowing
classification of variants with uncertain mutational
status.
For gene variants affecting SDH, the routinely
applied method is immunohistochemistry for SDHB
(SDHB-IHC), where staining intensity of tumoural
cells is compared with that of non-tumoural cells as
internal control [9]. Positively stained cells show a
granular pattern, whereas negative tissue at most has
a weak diffuse cytoplasmic blush. Importantly, the
protein is also degraded when subunits other than
SDHB are lost [10].
Another method to assess SDH functionality is based
on measurements of Krebs cycle metabolites by liquid
chromatography–mass spectrometry (LC–MS/MS), the
same instrument also now used for biochemical diagno-
sis of PPGL [11,12]. Metabolite profiling assesses the
functionality of SDH directly at the catalytic level by
measuring the precursor succinate and the product fuma-
rate. The ratio of these two metabolites, the tissue succi-
nate to fumarate ratio (SFR), can predict SDHx
mutations with a high sensitivity and specificity in PPGL
and is also now being applied to other tumours [11,13].
So far, there has been no formal comparison of the two
methods for predicting SDHx mutational status. The
nature of the techniques is different, one involving func-
tional assessment of enzyme activity versus histological
information about the presence of protein, but both offer-
ing complementary potential. Based on the ability of
machine learning to recognise patterns in data in a way
the human mind is not trained [14,15], we also investi-
gated whether such an approach can improve predictions
from metabolite data beyond the currently used SFR
[11,12]. Since one of the disadvantages of SDHB-IHC
relates to the subjective nature of image interpretation,
we further assessed whether local pathologists from dif-
ferent institutions scored slides differently from investi-
gators experienced in the method (referred to as
experts). An overall goal of the study was to explore
how SDHB-IHC and metabolite profiling might be use-
ful for streamlining diagnostic procedures for patients
and their families suffering from PPGLs due to SDH
impairment.
Materials and methods
Patient cohorts and tumour procurement
Tumour collections were approved under Intramural
Review Board protocols with informed consent signed
at each participating centre. A total of 397 patients with
401 different tumours were included in this study (sup-
plementary material, Table S1). The present report
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builds on our previously reported data onmetabolite pro-
files in 391 of these patients [12] by additional compari-
sons to immunohistopathological data and introduction
of machine learning for interpretation of metabolite pro-
files. Tumour material was collected as freshly frozen
(FF) and/or formalin-fixed and paraffin-embedded
(FFPE) samples. Patients were divided into two separate
cohorts (Table 1 and supplementarymaterial, Figure S1):
cohort 1 with 187 patients and 189 PPGLs included
results for matched metabolite profiling and SDHB-
IHC, whereas for cohort 2 (210 patients with 212
PPGLs) data from metabolite profiles, without availabil-
ity of SDHB-IHC, were included and used for training
the machine learning algorithms.
Genetic characteristics
Genetic testing, accomplished as previously described
[12], yielded findings of germline or somatic variants
in 18 genes in 49.1% (195/397) of patients (for simplic-
ity, only 11 are displayed in Table 1). Eleven patients
had variants of unknown significance in SDH genes,
classified as variants of unknown significance according
to the standards and guidelines of the American College
of Medical Genetics and Genomics and the Association
for Molecular Pathology [16]. In silico prediction of
mutation significance was performed on variants of
unknown significance using Mutation Taster [17], Poly-
phen [18], and SIFT [19].
Immunohistochemistry
FFPE tissue was sectioned and stained for SDHB using
rabbit polyclonal anti-SDHB (HPA002868, 1:400 dilu-
tion; Sigma-Aldrich, St Louis, MO, USA) according to
the local procedures of six different centres (Dresden,
Bethesda, Madrid, Florence, Nijmegen, and Rotterdam)
[9]. For 23% of tumours (44 samples), a tissue microar-
ray was constructed with three cores of 1.0 mm per sam-
ple. Local pathologists evaluated SDHB staining in one
slide per tumour and gave the results in four categories:
as positive, for the typical granular staining pattern; as
negative, for completely negative or weak diffuse
staining; as inconclusive, when both patterns were pre-
sent; or as non-informative, when tissue or staining arte-
facts were observed. For 50 samples, the SDHB-IHC
interpretations were as established previously, from
combined interpretations of seven expert pathologists
[20]; for these cases, results were rated as inconclusive
when fewer than five pathologists agreed. All patholo-
gists were blinded to the genetic status.
Interpretation of immunohistochemistry by
experienced pathologists
In a subset of cohort 1, termed subcohort 1b (see supple-
mentary material, Figure S1), SDHB-IHC slides from
the local centres were scanned and high-resolution
images were provided to a panel of three experts in
SDHB-IHC. Experts rated the staining according to the
four categories described above.
Metabolite measurements
Seven carboxylic acids of the Krebs cycle (succinate,
fumarate, malate, citrate, isocitrate, cis-aconitate,
α-ketoglutarate), 2-hydroxyglutarate, pyruvate, and lac-
tate were measured in methanol extracts of FF or FFPE
tissue by LC–MS/MS as detailed in supplementary
material, Supplementary materials and methods and
with resulting data provided in supplementary material,
Table S2. The cut-off for succinate:fumarate-based
interpretation was 97.7, as previously established [11].
Machine learning-assisted interpretation of
metabolite data
Tissue metabolite concentrations (ng/mg tissue) were
normalised to natural logarithmic values. These and their
ratios were used for formulating predictive models. To
establish the need for batch corrections (according to
measurement dates), a principal component analysis
was generated with the normalised metabolite values of
SDHx-mutated or SDHx-wild-type patients (supplemen-
tary material, Figure S2). There was a clear distinction
between the groups and none of the 27 different batches
showed any bias towards SDHx-mutated or SDHx-wild
type, allowing formulation of models without the need
for batch correction.
Feature selection for models was performed using
either logarithmically transformed values or ratios of
all metabolites against each other. The results of genetic
testing were used to separate patients into the categories
SDHx-mutated or SDHx-wild type. The ‘LDA
MATLAB’ function (MATLAB; MathWorks, Natick,
MA, USA) with application of a cross validation was
used to train the algorithm and generate models based
on linear discriminant analysis (LDA) [21]. Patients
from cohort 2 (excluding SDHx variants of unknown
significance and FFPE only tissue) were used to develop
the models and were randomly divided into training and
internal validation sets in ratios ranging from 50/50 to
90/10 in steps of 10%. This randomisation and model
generation was performed ten times and an average
Table 1. Diagnostic performance of SDHB-IHC compared to LC-MS/
MS based measurements of succinate:fumarate [SFR] in cohort 1.
SDHB-IHC* SFR p-value
Sensitivity [%] 85.2 [46/54] 88.1 [52/59] 0.774
Specificity [%] 92.5 [111/120] 99.2 [126/127] 0.021
Accuracy [%] 90.2 [157/174] 95.7 [178/186]
AUC 0.88 [0.82,0.91] 0.96 [0.89,0.98] 0.048
SFR
FP TN FN TP
SDHB-IHC FP [n = 9] 0 9 – –
FN [n = 8] – – 1 7
inc. [n = 12] 0 7 1 4
*Inconclusive samples (12) not included; inc. = inconclusive IHC results, FP: false
positive; FN: false negative; TP: true positives; TN: true negatives. Sensitivity,
specificity and accuracy are given as percentages with absolute numbers in
brackets. AUC is given as a ratio with CI in brackets.
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model was generated. In total, this resulted in five LDA
models for absolute values and five models for metabo-
lite ratios. The predictive models were applied to the
PPGLs of cohort 1 to calculate the likelihood of SDHx
mutations (external validation). Performance scores for
the different models on the training, internal validation,
and external validation sets were calculated (supplemen-
tary material, Figure S3) and the two best models
selected according to performance (supplementary mate-
rial, Figure S4). Selected models are referred to as LDA
A, using absolute values, and LDA B for metabolite
ratios. Since the models were built on values only from
FF tissues, ten samples with metabolite values for FF
and FFPE tissue were used to assess the suitability of
LDA B for PPGLs stored as FFPE tissues.
Calculation of diagnostic performance
Based on confusion matrices of genetically determined
versus predicted mutational status for SDHx, diagnostic
performance was assessed from estimates of sensitivity,
specificity, accuracy, and precision as detailed below:
sensitivity = TP/(TP + FN),
specificity = TN/(TN + FP),
accuracy = (TN + TP)/(TN + TP + FN + FP),
precision/positive predictive value = TP/(TP + FP),
F1-Score = 2 * [(precision * sensitivity)/(precision +
sensitivity)], where TP represents true positives, FN
false negatives, TN true negatives, and FP false
positives.
Statistics
Receiver operating characteristics (ROC) curves were pro-
duced using logistic regression. Areas under ROC curves
(AUCs) of the SDHB-IHC, SFR, LDA A, and LDA B
were compared using the Model Comparison tool in
JMP Pro (version 14; SAS, Cary, NC, USA). Logistic
regression models for combinations of SDHB-IHC with
any of the other models were produced in JMP and these
combined models’AUCs were compared with those from
using only SFR, LDA Model A or LDA Model B. As
there were different numbers of tumours available for the
different models, the AUC comparisons were performed
with all available tumours (186 versus 185 versus 186 ver-
sus 174) and with equal numbers (173 versus 173 versus
173 versus 173). Comparisons of sensitivity and specific-
ity between different predictive methods in the same
patient group utilised McNemar’s test for matched pairs
data, while comparisons of predictive methods in different
patient groups utilised Fisher’s exact test. Differences
were considered significant for P values below 0.05.
Results
Diagnostic performance of SDHB-IHC and
metabolite profiling by SFR
Among a total of 186 PPGLs (cohort 1 excluding three
variants of unknown significance), SDHB-IHC incor-
rectly predicted the SDH status in nine cases (false
positives) and missed SDH impairment in eight cases
(false negatives) (Table 1). In 12 tumours, the results
were deemed inconclusive according to heterogeneous
staining patterns or observer disagreements (the latter
applied to five cases with SDHB-IHC results taken from
a previously published study). SFR-based metabolite
profiling correctly predicted all nine false positives and
seven of eight false negatives, and all but one inconclu-
sive case were predicted correctly by the SFR. Diagnos-
tic specificity (p = 0.021) and AUC (p = 0.048) were
higher for SFR-based metabolite profiling than for
SDHB-IHC.
Machine learning-assisted interpretation of
metabolite profiling
Two different methods for machine learning-assisted
interpretation of metabolite profiles were compared with
the SFR (Table 2). Model LDA A uses four metabolites
and is restricted to measurements from frozen tissue,
where weight normalisation is possible. LDA B requires
input of ratios of tenmetabolites and is applicable to both
FF and FFPE specimens (supplementary material, Table
S3; supplementary material, Table S4 to produce the
ratios). Both models are provided as supplementary
material, MATLAB File S1 and MATLAB File S2 (for
MATLAB Model LDA A and B, respectively).
Our metabolite profiling-based models (LDAA, LDA
B, and SFR) were applied to 186 tumours (cohort 1). In
the case of LDAB, only 185 tumours of the 186 could be
used because measurement of one metabolite failed in
one tumour. Comparisons of metabolite profiling predic-
tions showed that the performance of LDA A was
improved over that of the SFR (p = 0.044), while there
were no significant differences between LDA B and
SFR or LDA A and LDA B (Figure 1 and Table 3).
SFR-based interpretation of metabolite profiles resulted
in seven false negatives, whereas LDA B produced six
and LDA A four false negatives (Table 2). The LDA
models calculate probabilities for the likelihood of an
SDHx mutation based on the metabolite inputs; for the
samples differently rated in LDA A and LDA B, the
probabilities were 57% and 99% for LDA A, and 42%
and 32% for LDA B, respectively (supplementary mate-
rial, Table S5).
It should also be noted that of the eight tumours where
SFR had an erroneous prediction, six were head and
neck paragangliomas with all seven false negatives car-
rying an SDHB, SDHC or SDHD mutation. When
LDA A and LDA B were applied to these samples,
LDA A correctly predicted three of the head and neck
paragangliomas, while LDA B correctly predicted two
of them (supplementary material, Table S5).
Since model generation of LDA B was performed
exclusively on data from freshly frozen (FF) samples,
we determined if the model could be applied to both
FF and FFPE tissues. For this purpose, LDA B was
applied to ten tumours where both FF and FFPE tissues
were available. LDA B correctly predicted the
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mutational status of all ten FFPE and nine of ten FF tis-
sues (supplementary material, Figure S5).
Combining metabolite profiling and SDHB-IHC for
best possible predictions on SDHx mutational status
We observed a trend towards improved predictions
when SDHB-IHC results were combined with the results
frommetabolite profiling compared with the latter alone,
supporting complementary utility of SDHB-IHC and
LC–MS/MS approaches (Figure 1). Metabolite profiling
complemented SDHB-IHC by correctly predicting the
SDHx mutational status of all but one case where
SDHB-IHC incorrectly predicted the mutational status.
In turn, SDHB-IHC correctly identified all but one of
the false-negative cases from metabolite profiling (sup-
plementary material, Table S5). With the available num-
ber of samples, statistical significance was not reached
(Table 3).
As it was observed that paragangliomas of the head
and neck region were classified more often as false neg-
atives with metabolite profiling, we compared the diag-
nostic sensitivity and specificity between
phaeochromocytomas, paragangliomas of the thorax or
abdomen, and head and neck paragangliomas (Table 4).
Although statistical significance was not reached, it was
apparent that the sensitivity was lowest for head and
neck paragangliomas with all four methods, SDHB-
IHC, SFR, LDAA, and LDAB. Specificity, on the other
hand, showed no regional bias with metabolite-based
methods, but was slightly lower for all paragangliomas
compared with phaeochromocytomas using
SDHB-IHC.
SDHB-IHC interpretations by local pathologists and a
panel of experienced experts
To address the question of whether expertise in SDHB-
IHC influences the interpretation of SDHB-IHC results,
we utilised a subset of samples in which interpretations
Table 3. Statistical comparisons of AUC differences.
Predictor versus Predictor AUC Difference p-value*
IHC SFR −0.070 0.048
IHC LDA A −0.092 0.004
IHC LDA B −0.086 0.012
SFR LDA A −0.023 0.044
SFR LDA B −0.016 0.533
LDA A LDA B 0.006 0.775
SFR SFR + IHC −0.031 0.113
LDA B LDA B + IHC −0.021 0.235
LDA A LDA A +IHC −0.014 0.301
*p<0.05 considered significant.
Figure 1. ROC curve comparisons for SDHB-IHC, metabolite profiling, and their combination. (A) ROC curves of SFR, SDHB-IHC, and their
combination. (B) ROC curves of LDA A, SDHB-IHC, and their combination. (C) ROC curves of LDA B, SDHB-IHC, and their combination.
Table 4. Comparison of predictive methods in the different subcategories of tumours.
PHEO PGL HNP HNP versus (PHEO + PGL)
n = 112 n = 30 n = 44 p-value*
IHC Sensitivity (%) 88.8 [8/9] 90.9 [20/22] 78.3 [18/23] 0.264
Specificity (%) 93.8 [91/97] 87.5 [7/8] 86.7 [13/15] 0.313
inconclusive (n) 6 0 6
SFR Sensitivity (%) 100 [9/9] 95.5 [21/22] 78.6 [22/28] 0.130
Specificity (%) 99 [102/103] 100 [8/8] 100 [16/16] 1.000
LDA A Sensitivity (%) 100 [9/9] 95.5 [21/22] 89.3 [25/28] 0.337
Specificity (%) 99 [102/103] 100 [8/8] 100 [16/16] 1.000
LDA B Sensitivity (%) 100 [8/8] 95.5 [21/22] 82.1 [23/28] 0.097
Specificity (%) 99 [102/103] 100 [8/8] 100 [16/16] 1.000
*calculated using Fisher’s exact test. HNP = Head and neck paraganglioma, PGL = paraganglioma, PHEO = Phaeochromocytomas.
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from local pathologists were compared with those of
experts (see supplementary material, Figure S1). Accu-
racy of predictions of SDHx mutations according to
SDHB-IHC indicated no significant differences between
local pathologists and experts, suggesting that SDHB-
IHC does not require specialised training (Table 5). In
71% of cases, all pathologists agreed and when at least
two experts on the panel agreed on the prediction (100
of 105 cases), they in turn agreed with the local patholo-
gist in 83 of these cases (79%) (supplementary material,
Figure S6). Agreement was higher in non-SDHx cases
(86%) than in SDHx-mutated cases (70%) (Table 5).
Amongst the samples with full agreement between all
pathologists, there were six cases (out of 75) with incor-
rect predictions. These six cases comprised five head and
neck paragangliomas with SDHx mutations and one
adrenal PPGL without an SDHx mutation, indicating
again that head and neck paragangliomas are the most
challenging specimens to interpret (supplementary
material, Table S5). Local pathologists rated nine slides
as inconclusive, whereas experts rated five slides as
inconclusive and six as non-informative. Only one
inconclusive case overlapped between the two groups,
indicating some variable subjectivity of interpretations.
Non-informative cases arose due to technical problems
with scanned images or staining of slides, such as related
to uneven staining or high background (example images
in supplementary material, Figure S7).
Re-evaluation of variants of unknown significance
in SDHx
Amongst the tumours evaluated, there were 11 patients
(three in cohort 1 and eight in cohort 2) with a variant
of unknown significance in one of the SDHx genes. Both
LDAmodels and the SFR were applied to the metabolite
profiles and compared with in silico predictions for pro-
tein changes (supplementary material, Table S6). Both
LDAmodels agreed in all four cases where the SFR pre-
dicted SDH impairment. In two of these cases, SDHB-
IHC was available, but did not support the metabolite-
based interpretations. LDA Model B predicted SDH
impairment in two further PPGLs, a splice site variant
in SDHA (NM_004168.3:c.457-1G>A) and an indel var-
iant in SDHC (NM_003001.3:c.256_257insTTT, p.
(Gly86delinsValCys). For the former, the same variant
was found in a second unrelated patient, where SDHB-
IHC showed negative staining, supporting the classifica-
tion as ‘likely pathogenic’. The missense variant of
SDHA, NM_004168.3:c.1772C>T, p.(Ala591Val), was
predicted to have no functional impact based on metab-
olite profiling and SDHB-IHC as interpreted by a local
pathologist. Experts, however, all agreed on a negative
staining pattern for SDHB. Two out of three in silico
protein prediction tools rated the variant as ‘disease
causing’ or ‘possibly damaging’.
Discussion
This study establishes for the first time that SDHB-IHC
and metabolite profiling provide complementary diag-
nostic tools for the prediction of SDH impairment in
PPGL tumour tissue. Moreover, we show that diagnostic
performance of metabolite profiling can be improved by
machine learning-assisted interpretation of metabolite
data and that there is a trend towards further improve-
ment by inclusion of findings from SDHB-IHC. We
therefore propose an approach that combines metabolite
profiling and SDHB-IHC to better facilitate identifying
or excluding SDH impairment when tumour material is
available, particularly for selected patients in whom
there is a suspicion of the presence of SDH mutation
and where genetic testing yields equivocal or negative
results or is unavailable. First, the high specificity of
metabolite profiling (99%) translates to high positive
predictive value of a positive result, strongly indicating
a mutation in an SDHx gene. If the genetic change iden-
tified is a variant of unknown significance, the predictive
models will, together with in silico prediction tools, aid
in determining whether the variant is pathogenic and
whether the patient and affected family members require
life-long surveillance. If metabolite profiling predicts no
SDH impairment, then SDHB-IHC provides utility to
exclude false negatives by metabolite profiling. Apply-
ing this approach to cohort 1 (excluding three variants
of unknown significance), we would have correctly pre-
dicted impairments of SDH in 185 of the 186 PPGLs,
providing an advantage over either method alone.
SDHB-IHC requires a simple setup and can be easily
incorporated into pathology workflows. Since our pre-
liminary evidence suggests that interpretation does not
require expert review, the technique is readily adoptable
anywhere. LC–MS/MS, on the other hand, requires spe-
cialised instrumentation and expertise, but is becoming
more and more available in clinical laboratories where
the instruments are used for many routine diagnostic
tests. While SDHB-IHC assesses presence of the pro-
tein, LC–MS/MS-based metabolite profiling provides
Table 5. SDHB-IHC interpretations of a panel of experienced
researchers versus local pathologists in cohort 1b.
Local Panel# p-value
Sensitivity [%] 80.0 [16/20] 65.0 [13/20] 0.250
Specificity [%] 92.4 [61/66] 98.5 [65/66] 0.125
Accuracy [%] 89.5 [77/86] 90.7 [78/86]
# Inconclusive/non-
informative cases * 9 11
Agreement
amongst panel
Agreement of panel [>2/3]
with local interpretations
3 2 0
non-SDHx (n = 73) 62 9 2 63 [86.3%]
SDHx (n = 30) 21 6 3 19 [70.0%]
SDHx VUS (n = 2) 2 0 0 1 [50.0%]
Total (n = 105) 85 15 5 83 [79.0%]
*Inconclusive cases were removed from the analysis.
#For the panel of experienced researchers, interpretations where at least two out
of three researchers agreed, were used.
VUS, Variant of Unknown Significance.
384 PWWallace et al
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2020; 251: 378–387
www.thejournalofpathology.com
information about functionality of the succinate complex
throughmeasurements of precursor and product metabo-
lites. There is also the added benefit of measuring a panel
of metabolites to identify impaired function of other
enzymes, such as fumarate hydratase and isocitrate
dehydrogenase [12,22]. Metabolite measurements also
address some of the limitations of SDHB-IHC: in partic-
ular, there is no subjective bias of interpretation and
there is always a numerical result rather than inconclu-
sive interpretations.
On the other hand, there are limitations of metabolite
profiling. Generating cut-offs or machine learning
models requires large numbers of samples and whether
such data are transferrable among laboratories (i.e.
method harmonisation) using LC–MS/MS is not yet
established. Another limitation of metabolite profiling
is tissue selection. False negatives can occur due to
excessive amounts of non-tumour tissue in the sample.
We suspect that this is also the reason for different pre-
dictions (probabilities for SDH impairment) produced
by LDA A and LDA B, since depending on the type of
stromal contaminant, metabolite levels will differ. One
possible solution, requiring interdisciplinary connec-
tions between anatomic and chemical diagnostic labora-
tories, is to assess tumour content first by haematoxylin
and eosin staining, perform macro-dissection of tumour
areas, and use this material for metabolite extraction.
Inter-observer variability of SDHB-IHC interpreta-
tions could be addressed by applying deep learning to
establish a pipeline for automated image interpretation,
as has been done for immunohistochemistry directed to
other purposes [14,23]. Machine learning was also dem-
onstrated to be suitable for cancer diagnosis on whole-
slide images [24]. Nevertheless, not only histology but
also biomarker interpretation and analysis of omics data
(transcriptomics, proteomics, and metabolomics) can
benefit from machine learning approaches [15]. A recent
example is the identification of PPGL-specific long
intergenic noncoding RNAs and their use for molecular
subtyping of PPGL patients [25].
In this study, we used pattern recognition and multidi-
mensional strategies from the field of artificial intelli-
gence for analysing metabolite data to gain information
beyond simple ratios such as the SFR. In this way,
machine learning offered improved diagnostic sensitiv-
ity. This was especially useful for identifying functional
impairment of SDH in head and neck paragangliomas,
for which false negatives can be a problem when relying
on the SFR [11]. We advise that the tumour content of
the input material for head and neck paragangliomas be
evaluated carefully and that further available methods
to test protein status, such as immunohistochemistry
for SDHB, SDHA or SDHD, be used [9,26,27].
While the predictive models generated in this study
were targeted towards identifying SDHx mutations, other
models could be generated based on measurements of
metabolites in the same panel to predict mutations and
functional deficiencies impacting other enzymes. Appli-
cation of the generated models (supplied as supplemen-
tary material, MATLAB Files S1 and S2) is relatively
straightforward since it only requires tissue concentra-
tions of measured metabolites or ratios of metabolites
(to calculate the matrices needed for input of this data into
the LDA models, see supplementary material, Table S4).
Results are provided as per cent probabilities of the
tumour harbouring an SDHx mutation. The interpretation
of ten metabolites is thereby converted into a simplified
single output variable to guide clinical decision-making.
With ongoing data collection for PPGLs and other
tumour entities, machine learning-assisted data interpre-
tation can be used to further stratify patients according to
mutational background or other clinically relevant fea-
tures as new models can be generated as more data
become available. This approach was also suggested in
the context of steroid metabolomics for the diagnosis
of adrenal cortical tumours [28].
A challenge of next-generation panel sequencing in
genetic testing is the interpretation of variants of unknown
significance. In our combined cohorts, a total of 11 vari-
ants of unknown significance in SDHx genes were identi-
fied. From those, four had elevated SFR indicating loss of
functionality; however, in silico predictions and SDHB-
IHC showed varying agreement. Such discrepancies
between SDHB-IHC and in silico predictions were
reported previously [29]. In two more tumours, where
SFR failed to indicate SDH impairment, the newmachine
learning-based LDA B predicted loss of SDH functional-
ity. At least in one of these cases, SDHA NM_004168.3:
c.457-1G>A, evidence suggests a true mutation.
Limitations of the present study are that SDHB-IHCdata
were not available for all patients and that immunohisto-
chemistry was performed in different centres to varying
standards and quality. The latter may partly explain the
lower level of agreement among pathologists for interpret-
ing SDHB-IHC than found in a previous study [20].
Despite this limitation, diagnostic sensitivity and specificity
for SDHB-IHC were in the range of former reports [9,20].
Although machine learning was only applied to metab-
olite data and not to images from SDHB-IHC, we could
show that there is potential for this approach to improve
diagnostic and prognostic workflows, especially when
data complexity is high. Our study also highlights the
benefit of interdisciplinary connections between physi-
cians, pathologists, clinical chemists, geneticists, and data
scientists. Byworking together, advanced genotypic strat-
ification of PPGLs can be expected to better facilitate tar-
geted therapies with increased efficacy and improved
patient outcomes [30–33].
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SUPPLEMENTARY MATERIAL ONLINE
Supplementary materials and methods
Figure S1. Flow diagram of patient and tumour sample numbers used in this study
Figure S2. PCA plot of all tumours showing grouping of SDHxmutations (black triangles) and SDHxwild types (open circles) based on the normalised
values of all ten measured metabolites
Figure S3. Performance of the models generated based on different ratios of how to separate cohort 2 into learning set and validation set
Figure S4. Performance of the two chosen models LDA A and LDA B
Figure S5. Comparison of predictions generated with LDA Model B from FFPE and FF tissue extracted metabolites
Figure S6.Distribution of true negatives (TN), true positives (TP), false positives (FP), and false negatives (FN) in cases of agreement between the panel
of researchers and local pathologists
Figure S7. Example images for SDHB-IHC scored by local pathologists and experts in the field of SDHB-IHC
Table S1. Characterisation of patient/tumour cohorts
Table S2. Tumour identifiers, clinical data, IHC results, and metabolite concentrations
Table S3. Input ratios for LDA model B in the order they need to be supplied in MATLAB
Table S4. Excel file to produce matrices for use in LDA models
Table S5. Results of all predictive methods where the tumour is misclassified by at least one of the methods
Table S6. Interpretation of metabolite profiles for SDHx VUS based on predictive models generated with linear discriminant analysis (LDA)
Table S7. Concentrations of pre-calibrators Pre-Cal 1–8
Table S8. Concentrations of internal standards in the Internal Standard Mix (IS-Mix)
Table S9. Concentrations of calibrators Cal 0–8
Table S10. Assay precision estimated using two quality control (QC) samples
Table S11.Multiple reaction monitoring transitions, fragmentation parameters,m and quantifiers
MATLAB File S1.Matlab_Model_LDA_A.mat – a MATLAB model for use with absolute metabolite concentrations
MATLAB File S2.Matlab_Model_LDA_B.mat – a MATLAB model for use with relative metabolite concentrations
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